[Disodium cromoglycat (intal) in the treatment of allergic states of the respiratory system (author's transl)].
Disodium cromoglycate (Intal) has been found several years ago to act as an reliable drug in the treatment of allergic states of the respiratory system. The effective mechanism seems to be its stabilizing function for circulating and sessile mast cells, thus avoiding the release of histamine and other vasoactive amines after an immunological or non-immunological stimulus. Although DSCG does not inhibit the binding of antigen to its antibody it must be given prophylactically before the antigen has access to the mast cells. Most efficiently DSCG is used in the treatment of the exogenous allergic asthma, and secondly in allergic rhinitis (70-90% success). Own observations confirm the effectiveness of the drug especially in patients with pollinosis. In addition it was found that DSCG can be used during hyposensitization procedures and that the drug does not influence the results of skin testing. At present there have been detected neither side-effects nor interactions with other drugs.
D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D003093:Colitis, Ulcerative / Q000188:drug therapy; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D008407:Mast Cells / Q000187:drug effects; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D004205:Cromolyn Sodium
Dinatrium cromoglicicum (Intal) in der Behandlung verschiedener allergischer Schleimhauterkrankungen.